Satellos Bioscience (TSE:MSCL)

TSX:MSCL

MSCL

Satellos Bioscience

RESEARCH TOOLSreports

Satellos Bioscience (MSCL) Price & Analysis

30 Followers

MSCL Stock Chart & Stats

C$8.25

C$0.01(1.16%)

At close: Jan 08 4:00 PM EST

C$8.25

C$0.01(1.16%)

Day’s Range― - ―

52-Week RangeC$6.24 - C$18.98

Previous CloseN/A

Volume29.01K

Average Volume (3M)178.54K

Market Cap

C$171.86M

Enterprise ValueC$41.10M

Total Cash (Recent Filing)C$27.66M

Total Debt (Recent Filing)C$0.00

Price to Earnings (P/E)―

Beta1.04

Next Earnings

Jun 02, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.69

Shares Outstanding20,831,190

10 Day Avg. Volume239,110

30 Day Avg. Volume178,539

Financial Highlights & Ratios

PEG Ratio0.11

Price to Book (P/B)4.17

Price to Sales (P/S)0.00

P/FCF Ratio-4.81

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

C$30.33

Price Target Upside267.69% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)-5.77

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe company has submitted regulatory applications for a global Phase 2 study to evaluate SAT-3247 in pediatric DMD patients, showing commitment to expanding clinical trials.

Financial PerformanceSatellos reported a lower net loss per share than consensus estimates, indicating better-than-expected financial performance.

Financial StabilitySatellos has cash and cash equivalents of approximately $35M, believed to be sufficient to fund operations into 2027, signaling financial stability.

Bears Say

Revenue ChallengesThe company reported no revenue for 3Q25, highlighting a challenge in generating income at this stage.

Satellos Bioscience News

Satellos initiated with an Outperform at Leerink

Leerink initiated coverage of Satellos (MSLE) with an Outperform rating and $20 price target The firm believes Satellos...

2h ago

MSLE

Satellos has ‘catalyst-rich; 2026, says H.C. Wainwright

H.C. Wainwright analyst Arthur He placed an $11 price target on Buy-rated Satellos (MSLE) Bioscience, saying the company...

7d ago

MSLE

Cantor starts Satellos with an Overweight on DMD therapy potential

As previously reported, Cantor Fitzgerald analyst Yanni Souroutzidis initiated coverage of Satellos (MSLE) with an Overweight rating and...

26d ago

MSLE

Satellos initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Satellos (MSLE) with an Overweight rating. Published first on TheFly – the ultimate...

26d ago

MSLE

Satellos Bioscience Inc. Common Stock trading resumes

10:09 EDT Satellos (MSLE) Bioscience Inc. Common Stock trading resumes Published first on TheFly – the ultimate source...

27d ago

MSLE

Satellos Bioscience Inc. Common Stock trading halted, volatility trading pause

10:04 EDT Satellos (MSLE) Bioscience Inc. Common Stock trading halted, volatility trading pause Published first on TheFly –...

27d ago

MSLE

Satellos presents interim SAT-3247 data at MDA Conference

Satellos (MSLE) Bioscience announced interim clinical and biomarker data for SAT-3247 at the Muscular Dystrophy Association, MDA, Clinical...

27d ago

MSLE

Satellos Bioscience Posts 2025 Results, Advances SAT-3247 Into Global Phase 2 Duchenne Trials

Satellos Bioscience ( ($TSE:MSCL) ) has issued an update. Satellos Bioscience reported full-year 2025 financial results on March...

10d ago

MSLE

Satellos Bioscience Unveils Positive Interim SAT-3247 Data in Duchenne Muscular Dystrophy at MDA 2026

Satellos Bioscience ( ($TSE:MSCL) ) has provided an update. On March 10, 2026, Satellos Bioscience reported interim data...

27d ago

MSLE

Satellos to Showcase New SAT-3247 DMD and FSHD Data at 2026 MDA Conference

Satellos Bioscience ( ($TSE:MSCL) ) has issued an update. On February 24, 2026, Toronto-based Satellos Bioscience said it...

1M ago

MSLE

Satellos Bioscience to Court Investors as Phase 2 DMD Program Advances

The latest announcement is out from Satellos Bioscience ( ($TSE:MSCL) ). On February 17, 2026, Satellos Bioscience said...

2M ago

MSLE

Satellos to Host February 24 Virtual KOL Event Showcasing SAT-3247 in Duchenne Muscular Dystrophy

Satellos Bioscience ( ($TSE:MSCL) ) has provided an announcement. On February 18, 2026, Satellos Bioscience Inc. announced it...

2M ago

MSLE

Satellos to Highlight Duchenne Drug Program at Series of Investor Conferences

Satellos Bioscience ( ($TSE:MSCL) ) has issued an announcement. Satellos Bioscience said its management team will present at...

2M ago

MSLE

Satellos Bioscience Doses First Patient in Phase 2 Pediatric Duchenne Study of SAT-3247

Satellos Bioscience ( ($TSE:MSCL) ) has shared an update. On February 12, 2026, Satellos Bioscience announced that it...

2M ago

MSLE

MSCL FAQ

What was Satellos Bioscience’s price range in the past 12 months?

Satellos Bioscience lowest stock price was C$6.24 and its highest was C$18.98 in the past 12 months.

What is Satellos Bioscience’s market cap?

Satellos Bioscience’s market cap is C$171.86M.

When is Satellos Bioscience’s upcoming earnings report date?

Satellos Bioscience’s upcoming earnings report date is Jun 02, 2026 which is in 57 days.

How were Satellos Bioscience’s earnings last quarter?

Satellos Bioscience released its earnings results on Mar 27, 2026. The company reported -C$0.694 earnings per share for the quarter, missing the consensus estimate of -C$0.517 by -C$0.177.

Is Satellos Bioscience overvalued?

According to Wall Street analysts Satellos Bioscience’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Satellos Bioscience pay dividends?

Satellos Bioscience does not currently pay dividends.

What is Satellos Bioscience’s EPS estimate?

Satellos Bioscience’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Satellos Bioscience have?

Satellos Bioscience has 20,831,190 shares outstanding.

What happened to Satellos Bioscience’s price movement after its last earnings report?

Satellos Bioscience reported an EPS of -C$0.694 in its last earnings report, missing expectations of -C$0.517. Following the earnings report the stock price went down -10.313%.

Which hedge fund is a major shareholder of Satellos Bioscience?

Currently, no hedge funds are holding shares in TSE:MSCL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Satellos Bioscience Stock Smart Score

Outperform

Fundamentals

Return on Equity

-51.42%

Trailing 12-Months

Asset Growth

-37.19%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Satellos Bioscience

Satellos Bioscience Inc., a biotechnology company, develops regenerative therapeutics to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system which recapitulates the muscle stem cell environment ex-vivo. Its lead program focuses on the discovery and development of a small molecule drug for the treatment of Duchenne. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.

Satellos Bioscience (MSCL) Earnings & Revenues

Historic Earnings Reports

MSCL Stock 12 Month Forecast

Average Price Target

C$30.33

▲(267.69% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"C$5","56":"C$56","17.75":"C$17.75","30.5":"C$30.5","43.25":"C$43.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":55.7873832,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$55.79</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30.334389615000003,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$30.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.34153038,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$15.34</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,17.75,30.5,43.25,56],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.35,11.999029476923077,15.648058953846153,19.29708843076923,22.946117907692305,26.59514738461538,30.244176861538463,33.89320633846154,37.542235815384615,41.19126529230769,44.840294769230766,48.48932424615384,52.138353723076925,{"y":55.7873832,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.35,10.041106893461539,11.732213786923078,13.423320680384617,15.114427573846154,16.805534467307695,18.49664136076923,20.18774825423077,21.87885514769231,23.56996204115385,25.261068934615388,26.952175828076925,28.643282721538462,{"y":30.334389615000003,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.35,8.887810029230769,9.425620058461538,9.963430087692307,10.501240116923077,11.039050146153846,11.576860175384615,12.114670204615384,12.652480233846154,13.190290263076923,13.728100292307692,14.265910321538462,14.80372035076923,{"y":15.34153038,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.76,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.56,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.2,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.28,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.519,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.24,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.4,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.92,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.99,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.85,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.35,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >